G
Guy Cinamon
Researcher at University of California, San Francisco
Publications - 8
Citations - 3310
Guy Cinamon is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Immune system & Cancer research. The author has an hindex of 3, co-authored 3 publications receiving 3078 citations.
Papers
More filters
Journal ArticleDOI
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
Mehrdad Matloubian,Charles G. Lo,Guy Cinamon,Matthew J. Lesneski,Ying Xu,Volker Brinkmann,Maria L. Allende,Richard L. Proia,Jason G. Cyster +8 more
TL;DR: It is established that S1P1 is essential for lymphocyte recirculation and that it regulates egress from both thymus and peripheral lymphoid organs.
Journal ArticleDOI
Follicular shuttling of marginal zone B cells facilitates antigen transport.
TL;DR: Marginal zone–follicle shuttling of marginal zone B cells provides an efficient mechanism for systemic antigen capture and delivery to follicular dendritic cells.
Journal ArticleDOI
Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone
Guy Cinamon,Mehrdad Matloubian,Matthew J. Lesneski,Ying Xu,Caroline Low,Theresa T. Lu,Theresa T. Lu,Richard L. Proia,Jason G. Cyster +8 more
TL;DR: It is reported that FTY720, a drug that targets sphingosine 1-phosphate (S1P) receptors, induced marginal zone B cell migration into follicles, and using gene-targeted mice, it is shown that S1P1 but not S1p3 was required for localization in the marginal zone.
Journal ArticleDOI
Abstract P075: NTX-1088, a potent first-in-class, anti-PVR mAb, restores expression and function of DNAM1 for optimal DNAM1-mediated antitumor immunity
Pini Tsukerman,Anas M. Atieh,A. F. Obeidat,Keren Paz,Guy Cinamon,Tihana Lenac Rovis,Paola Kucan Brlic,Lea Hiršl,Stipan Jonjić,Ofer Mandelboim +9 more
TL;DR: NTX-1088 as discussed by the authors is a first-in-class, potent, anti-PVR mAb being developed for the treatment of solid tumors, which can block the critical interaction between PVR and the costimulatory receptor DNAM1 (CD226).
Proceedings ArticleDOI
474 First-in-class anti-PVR mAb NTX1088 restores expression of DNAM1 and augments antitumor immunity
A. F. Obeidat,Anas M. Atieh,Alon Vitenshtein,Guy Cinamon,Keren Paz,Tihana Lenac Rovis,P. Brilc,Lea Hiršl,Ofer Mandelboim,Stipan Jonjić,Pini Tsukerman +10 more
TL;DR: NTX1088 as mentioned in this paper blocks the interaction between PVR and its receptors, leading to the restoration of DNAM1 expression and its immune activation function, while simultaneously neutralizing TIGIT and CD96 inhibitory signals in immune cells.